1. Combining Nilotinib and Imatinib Improves the Outcome of Imatinib-Resistant Blast Phase CML.
- Author
-
Zhu, Guang-rong, Ji, Ou, Ji, Jian-min, Zhang, Ya-cheng, Wu, Yu, Yu, Hui, Jiang, Peng-Jun, and Shen, Qun
- Subjects
IMATINIB ,DRUG resistance ,CHRONIC myeloid leukemia ,PROGNOSIS ,BONE marrow - Abstract
Imatinib resistance is an important hurdle in the treatment of chronic myeloid leukemia (CML), and CML patients with this drug resistance are often given a dismal prognosis. In this case report, an imatinib-refractory blast phase CML patient was treated with a combination of imatinib and nilotinib. A complete hematologic response was achieved within 3 months, the drug combination was well tolerated, and there was a relatively long bone-marrow complete remission. These results suggest that combining imatinib and nilotinib treatment may improve the outcome of imatinib-resistant CML patients in the blast phase. We hypothesize regarding the possible mechanism for the effectiveness of the drug combination by reviewing the recent literature. Copyright © 2012 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF